查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
2023-2030 年偏頭痛治療的全球市場
市場調查報告書
商品編碼
1279679

2023-2030 年偏頭痛治療的全球市場

Global Migraine Drugs Market - 2023-2030
出版日期: | 出版商: DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

市場概覽

全球偏頭痛藥物市場預計將在 2022 年達到 40.358 億美元，到 2030 年達到 97.911 億美元，增長勢頭良好。 由於全球偏頭痛的增加，人們對偏頭痛及其治療的認識不斷提高，預計在預測期內（2023-2030 年），偏頭痛治療市場的複合年增長率將達到 12.1%。 此外，不斷增長的需求和對安全有效治療的研究和開發的增加預計將推動市場增長。

市場動態

在預測期內，治療的進步有望推動偏頭痛治療市場的增長

預計在預測期內，新藥和新藥物輸送系統（針頭注射、滴鼻劑）等治療方法的進步將推動全球偏頭痛治療市場的增長。 例如，與在 30 分鐘內表現良好的現有治療相比，這些藥物中的一些可以在偏頭痛發作後 2 至 4 小時內得到治療。

臨床研究資金的增加為偏頭痛藥物市場帶來了增長機會

增加對主要市場參與者的資助確保了全球偏頭痛治療市場在未來幾年的增長機會。 例如，2022 年 8 月，專注於偏頭痛護理的以色列數字療法設計師 Theranica 籌集了約 4500 萬美元的 C 系列資金。

COVID-19 影響分析

對 COVID-19 的分析包括 COVID 之前、COVID 和 COVID 之後的情景、價格動態（與 COVID 之前的情景相比，大流行期間和之後的價格變動）、供需範圍（由於供應和需求的變化貿易限制、封鎖和後續問題）；努力）也將被解釋。

俄烏衝突分析

烏克蘭和俄羅斯都是國際臨床試驗活動的廣泛基地。 對烏克蘭的襲擊可能會破壞全球藥物開發成果，包括偏頭痛藥物，因為這兩個國家的潛在招募地點都失敗了。 軍事衝突造成的中斷對醫療保健產生重大影響，包括偏頭痛藥物。

全球經濟衰退影響分析

醫療保健行業也不能完全免受衰退的影響。 但由於其固有的性質，它比其他行業處理得更好。 然而，隨著通脹繼續上升，經濟衰退危機威脅著市場。 持續衰退導致的緊張局勢加劇可能會在未來幾年對市場產生重大影響。

人工智能影響分析

2023 年 5 月，虛擬臨床試驗平台提供商 Healint 與日本埼玉醫科大學醫院合作，試驗如何利用 AI 檢測偏頭痛。 該研究將由 Healint 的數據平台 Migraine Buddy 提供支持。 這項研究探討了 AI 如何診斷、調查和查明患者的致命情況，以及它如何在未來幾年對全球偏頭痛藥物市場產生積極影響。

內容

第一章研究方法與範圍

  • 調查方法
  • 調查目的和範圍

第 2 章定義和概述

第 3 章執行摘要

  • 片段類型
  • 按給藥途徑分類的片段
  • 按銷售渠道分類的摘要

第四章市場動態

  • 影響因素
    • 主持人
      • 開發具有成本效益的新產品
      • 市場開發
    • 約束因素
      • 嚴格的監管機構
    • 機會
    • 政府舉措
    • 影響分析

第五章行業分析

  • 波特的五力分析
  • 監管分析
  • 價格分析
  • 流行病學分析
  • 專利分析

第 6 章 COVID-19 分析

  • COVID-19 分析
    • COVID-19 之前的情景
    • 當前的 COVID-19 情景
    • COVID-19 後或未來情景
  • COVID-19 期間的價格和動態
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略舉措
  • 結論

第七章俄烏衝突分析

第八章全球經濟衰退分析

第9章人工智能的影響分析

第 10 章按類型

  • 預防醫學
  • 預防醫學

第11章給藥途徑

  • 口語
  • 注射
  • 其他

第 12 章分銷渠道

  • 醫院藥房
  • 零售藥房
  • 在線藥店

第13章按地區

  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 其他歐洲
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他南美洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 澳大利亞
    • 其他亞太地區
  • 中東和非洲

第14章競爭格局

  • 競爭場景
  • 市場份額分析
  • 併購分析

第十五章公司簡介

  • 雅培實驗室
    • 公司簡介
    • 產品組合和概述
    • 財務摘要
    • 主要發展狀況
  • AbbVie Inc
  • Allergan Plc.
  • AstraZeneca PLC.
  • Eisai Co., Ltd.
  • Endo International Plc.
  • GlaxoSmithKline Plc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Johnson & Johnson

第16章 附錄

簡介目錄
Product Code: PH2530

Market Overview

The global migraine drugs market reached USD 4,035.8 million in 2022 and is projected to witness lucrative growth by reaching up to USD 9,791.1 million by 2030. The migraine drugs market is expected to exhibit a CAGR of 12.1% during the forecast period (2023-2030), owing to the increase in the preponderance of migraine globally and the increase in awareness regarding migraine and their therapy choices. Additionally, a rise in demand for secure and efficacious therapy and an increase in research and development is anticipated to promote the growth of the market.

Market Dynamics

The Treatment Advancements are Expected to Drive the Migraine Drugs Market Growth During the Forecast Period.

The treatment advancements such as the advancements in new drugs and new drug delivery systems (needle injections, nasal sprays) are expected to drive the global migraine drugs market growth during the forecast period. For example, a few of these medications can treat migraine 2-4 hours into an attack when compared to the pre-existing therapies that perform satisfactorily if administered within 30 minutes.

The Increasing Funding for Clinical Research is Providing Growth Opportunities for Migraine Drugs Market.

The growing funding to the key market players is ensuring growth opportunities for the global migraine drugs market in the upcoming years. For instance, in August 2022, Theranica, an Israel-based digital therapeutics designer concentrated on migraine care, raised around USD 45 million in Series C funding.

COVID-19 Impact Analysis

The COVID-19 analysis includes Pre-COVID Scenario, COVID Scenario, and Post-COVID Scenario along with pricing dynamics (including pricing change during and post-pandemic comparing it to pre-COVID scenarios), demand-supply spectrum (shift in demand and supply owing to trading restrictions, lockdown, and subsequent issues), government initiatives (initiatives to revive market, sector or industry by government bodies) and manufacturers strategic initiatives (what manufacturers did to mitigate the COVID issues will be covered here).

Russia-Ukraine Conflict Analysis

Ukraine and Russia are both extensive bases for international clinical trial activities. The attack on Ukraine may cause an underpowering of global drug development outcomes including drugs for migraine with the failure of prospective recruitment locations for both nations. The turmoil and disorder induced by military confrontation have a significant influence over healthcare including migraine drugs and others.

Global Recession Impact Analysis

The healthcare industry is not completely immune to recession, as healthcare institutions thought firings and employing freezes during past financial downturns. That stated, the industry does cope finer than other sectors because of its essential nature. However, the danger of recession threatens the market as inflation persists increasing. The elevated extent of tension about the persistent recession could hold a substantial influence on the scleroderma market over the following few years.

Artificial Intelligence Impact Analysis

In May 2023, Healint, a virtual clinical trial platform-delivering company, partnered with the Saitama Medical University Hospital in Japan to experiment with how AI could be employed to detect migraines. The investigation is fueled by Healint's Migraine Buddy platform for data. The research will investigate how AI could diagnose patients, pick therapies and pinpoint possible fatal circumstances positively impacting the global migraine drugs market in the upcoming years.

Segment Analysis

The global migraine drugs market is segmented based on phase, design, indication, service, and region.

The Retail Pharmacy Segment is Estimated to Hold a 35% Share of the Global Market by 2030.

The majority of migraine preventive or abortive medications are intended for relieving the induced symptoms and averting or subsiding the migraine attack. These medications are primarily analgesics and OTC medicines that are easily available from retail pharmacies. Therefore, the retail pharmacy segment is estimated to hold a dominant share of the global migraine drugs market accounting for around 35.0% of the total market throughout the forecast period.

Geographical Analysis

Europe is Estimated to Hold the Second-largest Share of the Global Migraine Drugs Market During the Forecast Period.

Europe is estimated to hold around 28.2% of the total migraine drugs market owing to the high spending on migraine by European individuals and the efforts by various organizations to spread awareness about migraine in this region. For instance, according to a new article published in September 2022, at the recent Migraine Trust International Symposium, the world's longest-established headache medical conference, supporters gathered jointly to reach for enhanced guidelines for those impacted by migraine. Migraine persists to be a considerable public health issue across Europe costing European economies an assessed €55 billion yearly in immediate and indirect health care costs.

Competitive Landscape

The major global players in the market include: Allergen, Eisai, Ltd., AstraZeneca plc, Abbott Laboratories, Eisai Co., Ltd., Endo International Plc., GlaxoSmithKline Plc., Merck & Co., Inc., Pfizer Inc., and Johnson & Johnson among others.

Why Purchase the Report?

  • To visualize the global migraine drugs market segmentation based on type, route of administration, distribution channel, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of migraine drugs market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global migraine drugs market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Type
  • 3.2. Snippet by Route of Administration
  • 3.3. Snippet by Distribution Channel

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Development Of Various New Cost-Effective Products
      • 4.1.1.2. Market Developments
    • 4.1.2. Restraints
      • 4.1.2.1. Stringent Regulatory Authorities
    • 4.1.3. Opportunity
    • 4.1.4. Government Initiatives
    • 4.1.5. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Regulatory Analysis
  • 5.3. Pricing Analysis
  • 5.4. Epidemiological Analysis
  • 5.5. Patent Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Before COVID-19 Scenario
    • 6.1.2. Present COVID-19 Scenario
    • 6.1.3. Post COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturers' Strategic Initiatives
  • 6.6. Conclusion

7. Russia-Ukraine Conflict Analysis

8. Global Recession Analysis

9. Artificial Intelligence Impact Analysis

10. By Type

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 10.1.2. Market Attractiveness Index, By Type
  • 10.2. Abortive Medicine
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Preventive Medicine

11. By Route of Administration

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 11.1.2. Market Attractiveness Index, By Route of Administration
  • 11.2. Oral *
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Injectable
  • 11.4. Others

12. By Distribution Channel

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.1.2. Market Attractiveness Index, By Distribution Channel
  • 12.2. Hospital Based Pharmacies
    • 12.2.1. Introduction
    • 12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 12.3. Retail Pharmacies
  • 12.4. Online Pharmacies

13. By Region

  • 13.1. Introduction
    • 13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 13.1.2. Market Attractiveness Index, By Region
  • 13.2. North America
    • 13.2.1. Introduction
    • 13.2.2. Key Region-Specific Dynamics
    • 13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.2.6.1. The U.S.
      • 13.2.6.2. Canada
      • 13.2.6.3. Mexico
  • 13.3. Europe
    • 13.3.1. Introduction
    • 13.3.2. Key Region-Specific Dynamics
    • 13.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.3.6.1. Germany
      • 13.3.6.2. The U.K.
      • 13.3.6.3. France
      • 13.3.6.4. Italy
      • 13.3.6.5. Spain
      • 13.3.6.6. Rest of Europe
  • 13.4. South America
    • 13.4.1. Introduction
    • 13.4.2. Key Region-Specific Dynamics
    • 13.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.4.6.1. Brazil
      • 13.4.6.2. Argentina
      • 13.4.6.3. Rest of South America
  • 13.5. Asia-Pacific
    • 13.5.1. Introduction
    • 13.5.2. Key Region-Specific Dynamics
    • 13.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 13.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 13.5.6.1. China
      • 13.5.6.2. India
      • 13.5.6.3. Japan
      • 13.5.6.4. Australia
      • 13.5.6.5. Rest of Asia-Pacific
  • 13.6. Middle East and Africa
    • 13.6.1. Introduction
    • 13.6.2. Key Region-Specific Dynamics
    • 13.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
    • 13.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 13.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

14. Competitive Landscape

  • 14.1. Competitive Scenario
  • 14.2. Market Share Analysis
  • 14.3. Mergers and Acquisitions Analysis

15. Company Profiles

  • 15.1. Abbott Laboratories
    • 15.1.1. Company Overview
    • 15.1.2. Type Portfolio and Description
    • 15.1.3. Financial Overview
    • 15.1.4. Key Developments
  • 15.2. AbbVie Inc
  • 15.3. Allergan Plc.
  • 15.4. AstraZeneca PLC.
  • 15.5. Eisai Co., Ltd.
  • 15.6. Endo International Plc.
  • 15.7. GlaxoSmithKline Plc.
  • 15.8. Merck & Co., Inc.
  • 15.9. Pfizer Inc.
  • 15.10. Johnson & Johnson

LIST NOT EXHAUSTIVE

16. Appendix

  • 16.1. About Us and Services
  • 16.2. Contact Us